Abstract
Smoking cessation therapies are among the most cost-effective preventive healthcare measures. Varenicline is a relatively new drug developed especially for this purpose, and it has been shown to achieve better quit rates than nicotine replacement therapies and the non-nicotine-based drug, bupropion, which has been in use for some years. The cost-effectiveness of varenicline depends on the cost of the therapy and the cost-savings achieved through reduced morbidity and mortality; several investigations, based on the situation in different countries, indicate that varenicline either finances itself fully through the cost-savings achieved or offers additional life-years at a lower price than that paid elsewhere in the healthcare sector.
| Original language | English |
|---|---|
| Journal | Expert Review of Pharmacoeconomics & Outcomes Research |
| Volume | 9 |
| Issue number | 3 |
| Pages (from-to) | 215-221 |
| Number of pages | 7 |
| ISSN | 1473-7167 |
| DOIs | |
| Publication status | Published - 2009 |